Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
"We are focused on advancing the development of our lead program, QLS-215, as a differentiated and potentially the most patient-friendly treatment option for the chronic treatment of patients with hereditary angioedema to prevent attacks," said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. "We anticipate that our first clinical trial with QLS-215 could demonstrate clinical proof of concept of its differentiated profile and long antibody half-life. Initial results from this trial are anticipated